
BALCHEM CORP
BCPCNASDAQTrading Snapshot
- Day Range
- $178.25 โ $181.56
- 52-Week Range
- $139.17 โ $183.90
- Volume
- $2.44B
- Avg Volume
- $2.47B
- Shares Outstanding
- 32.1M
- Next Earnings
- Sep 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.04B
- Last Q Revenue
- $284M
- P/E Ratio
- 35.0
- P/S Ratio
- 5.3x
- EPS (TTM)
- $5.10
- Dividend Yield
- 0.54%
Why Investors Own BCPC
- โHigh-growth profile โ revenue up +42.8% YoY with expanding US Equity exposure.
- โHealthy economics โ 76% gross margin and 13% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About BALCHEM CORP
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

Snowflake To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on top names. Barclays raised DAR's target to $65, BTIG boosted SNOW's target to $340, and JP Morgan upgraded LYB to Overweight.
HC Wainwright & Co. Maintains Buy on Balchem, Raises Price Target to $215
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Balchem (NASDAQ:BCPC) with a Buy and raises the price target from $190 to $215.
Balchem: It's A Buy From Me After Posting Strong Q2 Results

Balchem Corporation (BCPC) Q2 2026 Earnings Call Transcript
Balchem Corporation (BCPC) Q2 2026 Earnings Call July 31, 2026 11:00 AM EDTCompany ParticipantsCarl Bengtsson - Executive VP, CFO, Treasurer and GM of...

Balchem (NASDAQ:BCPC) Beats Q2 Estimates as Record Sales and Adjusted EPS Top Expectations
Balchem Q2 earnings beat estimates with record sales and EPS, but stock reaction muted amid lacking guidance.

Balchem Corporation 2026 Q2 - Results - Earnings Call Presentation
2026-07-31. The following slide deck was published by Balchem Corporation in conjunction with their 2026 Q2 earnings call.